High phenylalanine concentrations in the brain due to dysfunctional phenylalanine hydroxylase (Pah) are considered to account for mental retardation in phenylketonuria (PKU). In this study, we treated hippocampal cultures with the amino acid in order to determine the role of elevated levels of phenylalanine in PKU-related mental retardation. Synapse density and dendritic length were dramatically reduced in hippocampal cultures treated with phenylalanine. Changes in cofilin expression and phosphorylation status, which were restored by NMDA, as well as reduced activation of the small GTPase Rac1, likely underlie these structural alterations. In the Pah(enu2) mouse, which carries a mutated Pah gene, we previously found higher synaptic density due to delayed synaptic pruning in response to insufficient microglia function. Microglia activity and C3 complement expression, both of which were reduced in the Pah(enu2) mouse, however, were unaffected in hippocampal cultures treated with phenylalanine. The lack of a direct effect of phenylalanine on microglia is the key to the opposite effects regarding synapse stability in vitro and in the Pah(enu2) mouse. Judging from our data, it appears that another player is required for the inactivation of microglia in the Pah(enu2) mouse, rather than high concentrations of phenylalanine alone. Altogether, the data underscore the necessity of a lifelong phenylalanine-restricted diet.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.expneurol.2016.04.013DOI Listing

Publication Analysis

Top Keywords

pahenu2 mouse
16
hippocampal cultures
12
phenylalanine
8
mental retardation
8
cultures treated
8
treated phenylalanine
8
phenylketonuria direct
4
direct indirect
4
indirect effects
4
effects phenylalanine
4

Similar Publications

BACKGROUNDThe toxic accumulation of phenylalanine (Phe) in the brain underlies the neurological presentation of phenylketonuria (PKU). Solute carrier family 6 member 19 (SLC6A19) is the major transporter responsible for the (re)absorption of Phe in the kidney and intestine. Here, we describe the characterization of the first small molecule SLC6A19 inhibitor to enter clinical development for the treatment of PKU.

View Article and Find Full Text PDF

New findings about neuropathological outcomes in the PKU mouse throughout lifespan.

Mol Genet Metab

October 2024

Department of Biomolecular Sciences, University of Urbino "Carlo Bo", via Ca' Le Suore 2, 61029 Urbino (PU), Italy; EryDel SpA, via Antonio Meucci 3, 20091 Bresso (MI), Italy.

Phenylketonuria (PKU, OMIM 261600) is a genetic disorder caused by a deficiency of the hepatic enzyme phenylalanine hydroxylase (PAH). If left untreated, PKU leads to systemic phenylalanine (Phe) accumulation, which can result in irreversible brain damage and intellectual disabilities. In the last 60 years, early and strict dietary restriction of phenylalanine (Phe) intake proved to prevent the severe clinical phenotype of untreated PKU.

View Article and Find Full Text PDF

Pathophysiology of osteopenia in phenylalanine hydroxylase (PAH) deficient phenylketonuria (PKU) is poorly characterized. The Pah mouse is universally osteopenic where dietary phenylalanine (Phe) management with amino acid defined chow does not improve bone density. We previously demonstrated Pah osteopenia owes to a skeletal stem cell (SSC) developmental deficit mediated by energy dysregulation and oxidative stress.

View Article and Find Full Text PDF

Osteopenia is an under-investigated clinical presentation of phenylalanine hydroxylase (PAH)-deficient phenylketonuria (PKU). While osteopenia is not fully penetrant in human PKU, the Pah mouse is universally osteopenic and ideal to study the phenotype. We determined Pah mesenchymal stem cells (MSCs) are developmentally impaired in the osteoblast lineage.

View Article and Find Full Text PDF
Article Synopsis
  • Classical phenylketonuria (PKU) results from a liver enzyme deficiency that leads to high levels of phenylalanine (Phe), causing various neurological issues, including impaired brain development and mental retardation.
  • Metabolomic analysis of PKU-affected mouse tissues revealed an overabundance of Phe and related compounds in the blood and liver, while the brain showed signs of oxidative stress and energy dysregulation.
  • Findings indicate that while PKU primarily stems from liver issues, the brain experiences unique metabolic disturbances linked to neurological symptoms, highlighting the complexity of PKU's impact on brain health.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!